
## Marianna Amboni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5740396/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mild Cognitive Impairment Subtypes Are Associated With Peculiar Gait Patterns in Parkinson's Disease. Frontiers in Aging Neuroscience, 2022, 14, 781480.	3.4	7
2	Interplay between gait and neuropsychiatric symptoms in Parkinson's Disease. European Journal of Translational Myology, 2022, 32, .	1.7	3
3	Vitamin D as a possible biomarker of mild cognitive impairment in parkinsonians. Aging and Mental Health, 2021, 25, 1998-2002.	2.8	7
4	Machine Learning Approaches in Parkinson's Disease. Current Medicinal Chemistry, 2021, 28, 6548-6568.	2.4	27
5	Metabolomics in Parkinson's disease. Advances in Clinical Chemistry, 2021, 104, 107-149.	3.7	7
6	Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinson's disease. Scientific Reports, 2021, 11, 8936.	3.3	24
7	Gait analysis may distinguish progressive supranuclear palsy and Parkinson disease since the earliest stages. Scientific Reports, 2021, 11, 9297.	3.3	16
8	Neuropsychological correlates of prospective memory: A comparison between tremor-dominant Parkinson's disease and cervical dystonia. Journal of Clinical Neuroscience, 2021, 87, 156-161.	1.5	1
9	Gait Analysis in Progressive Supranuclear Palsy Phenotypes. Frontiers in Neurology, 2021, 12, 674495.	2.4	8
10	Motor dual task with eyes closed improves postural control in patients with functional motor disorders: A posturographic study. Gait and Posture, 2021, 88, 286-291.	1.4	8
11	Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study. Frontiers in Neurology, 2021, 12, 711358.	2.4	7
12	<scp><i>GBA</i>â€Related</scp> Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort. Movement Disorders, 2020, 35, 2106-2111.	3.9	83
13	Classifying patients affected by Parkinson's disease into freezers or non-freezers through machine learning. , 2020, , .		7
14	A quantitative analysis of muscular co-activation on EMG signals in spastic patients treated with Botulinum toxin. , 2020, , .		1
15	Machine learning can detect the presence of Mild cognitive impairment in patients affected by Parkinson's Disease. , 2020, , .		20
16	Prevalence of heterozygous mutations in Niemann-Pick type C genes in a cohort of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2020, 79, 9-10.	2.2	4
17	The role of the motor subtypes on the relationship between anxiety and cognitive dysfunctions in Parkinson's disease. Journal of Neural Transmission, 2020, 127, 893-898.	2.8	3
18	Classifying Different Stages of Parkinson's Disease Through Random Forests. IFMBE Proceedings, 2020, , 1155-1162.	0.3	20

#	Article	IF	CITATIONS
19	Using gait analysis' parameters to classify Parkinsonism: A data mining approach. Computer Methods and Programs in Biomedicine, 2019, 180, 105033.	4.7	54
20	Validation of the Italian version of the PSP Quality of Life questionnaire. Neurological Sciences, 2019, 40, 2587-2594.	1.9	5
21	Prospective memory in Parkinson's disease: the role of the motor subtypes. Journal of Neurology, 2019, 266, 2505-2511.	3.6	4
22	Validation of the Italian version of carers' quality-of-life questionnaire for parkinsonism (PQoL) Tj ETQq0 0 (	) rgBT /Ove 1.9	rloçk 10 Tf 50
23	Parkinson's disease management and impulse control disorders: current state and future perspectives. Expert Review of Neurotherapeutics, 2019, 19, 495-508.	2.8	7
24	Interoceptive processing deficit: A behavioral marker for subtyping Parkinson's disease. Parkinsonism and Related Disorders, 2018, 53, 64-69.	2.2	24
25	Cognitive correlates of "pure apathy―in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 53, 101-104.	2.2	27
26	Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. Journal of Neurology, 2018, 265, 2211-2220.	3.6	32
27	Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. , 2018, 265, 2211.		1
28	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	2.2	44
29	Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease. Parkinsonism and Related Disorders, 2017, 37, 106-110.	2.2	28
30	Assessment of apathy minimising the effect of motor dysfunctions in Parkinson's disease: a validation study of the dimensional apathy scale. Quality of Life Research, 2017, 26, 2533-2540.	3.1	22
31	Bisphenol A glucuronidation in patients with Parkinson's disease. NeuroToxicology, 2017, 63, 90-96.	3.0	24
32	Impact of anxiety, apathy and reduced functional autonomy on perceived quality of life in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 43, 114-117.	2.2	43
33	Resting-state brain networks in patients with Parkinson's disease and impulse control disorders. Cortex, 2017, 94, 63-72.	2.4	53
34	Serum IGF-1 is associated with cognitive functions in early, drug-naÃ⁻ve Parkinson's disease. PLoS ONE, 2017, 12, e0186508.	2.5	30
35	Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. Parkinsonism and Related Disorders, 2016, 28, 137-140.	2.2	62
36	Gender and non motor fluctuations in Parkinson's disease: A prospective study. Parkinsonism and Related Disorders, 2016, 27, 89-92.	2.2	42

MARIANNA AMBONI

#	Article	IF	CITATIONS
37	Anxiety in early Parkinson's disease: Validation of the Italian observer-rated version of the Parkinson Anxiety Scale (OR-PAS). Journal of the Neurological Sciences, 2016, 367, 158-161.	0.6	21
38	Caffeine consumption and the 4-year progression of de novo Parkinson's disease. Parkinsonism and Related Disorders, 2016, 32, 116-119.	2.2	24
39	Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment. Lancet Neurology, The, 2016, 15, 1063-1074.	10.2	86
40	Music Therapy for Motor and Nonmotor Symptoms of Parkinson's Disease: A Prospective, Randomized, Controlled, Singleâ€Blinded Study. Journal of the American Geriatrics Society, 2016, 64, e36-9.	2.6	16
41	Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study. Journal of Neural Transmission, 2016, 123, 1399-1402.	2.8	36
42	A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. Sleep, 2016, 39, 405-412.	1.1	73
43	Italian survey on intraduodenal levodopa gel treatment in advanced Parkinson disease: State of the art 10 years after marketing. Parkinsonism and Related Disorders, 2016, 22, e97-e98.	2.2	0
44	Serum uric acid is associated with apathy in early, drug-naÃ⁻ve Parkinson's disease. Journal of Neural Transmission, 2016, 123, 371-377.	2.8	9
45	Cortical thickness changes in patients with Parkinson's disease and impulse control disorders. Parkinsonism and Related Disorders, 2016, 24, 119-125.	2.2	76
46	Olfaction in Homozygous and Heterozygous <scp>SYNJ</scp> 1 Arg258Gln Mutation Carriers. Movement Disorders Clinical Practice, 2015, 2, 413-416.	1.5	0
47	Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients. Parkinsonism and Related Disorders, 2015, 21, 489-493.	2.2	97
48	Quitting smoking: An early non-motor feature of Parkinson's disease?. Parkinsonism and Related Disorders, 2015, 21, 216-220.	2.2	19
49	Short-latency afferent inhibition in patients with Parkinson's disease and freezing of gait. Journal of Neural Transmission, 2015, 122, 1533-1540.	2.8	22
50	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. Movement Disorders, 2015, 30, 373-378.	3.9	41
51	Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease. Journal of Neurology, 2015, 262, 425-434.	3.6	175
52	Mild Cognitive Impairment in newly diagnosed Parkinson's disease: AÂlongitudinal prospective study. Parkinsonism and Related Disorders, 2015, 21, 1219-1226.	2.2	113
53	Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale. Journal of Neurology, 2014, 261, 2319-2328.	3.6	74
54	The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain, 2014, 137, 2731-2742.	7.6	251

Marianna Amboni

#	Article	IF	CITATIONS
55	Pallidal stimulation in atypical pantothenate kinaseâ€associated neurodegeneration: Sixâ€year followâ€up. Movement Disorders, 2014, 29, 276-277.	3.9	6
56	Valproateâ€Induced Generalized Choreoathetosis. Movement Disorders Clinical Practice, 2014, 1, 271-272.	1.5	6
57	The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. Neurological Sciences, 2014, 35, 379-383.	1.9	42
58	Do Subjective Memory Complaints Herald the Onset of Mild Cognitive Impairment in Parkinson Disease?. Journal of Geriatric Psychiatry and Neurology, 2014, 27, 276-281.	2.3	64
59	Comment on Szewczyk-Krolikowski etÂal.: The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism and Related Disorders, 2014, 20, 1319-1320.	2.2	5
60	Dopamine transporter availability in motor subtypes of de novo drug-naÃ⁻ve Parkinson's disease. Journal of Neurology, 2014, 261, 2112-2118.	3.6	37
61	Gender differences in non-motor symptoms in early Parkinson's disease: A 2-years follow-up study on previously untreated patients. Parkinsonism and Related Disorders, 2014, 20, 850-854.	2.2	60
62	How does smoking affect olfaction in Parkinson's disease?. Journal of the Neurological Sciences, 2014, 340, 215-217.	0.6	13
63	Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?. Parkinsonism and Related Disorders, 2014, 20, 772-775.	2.2	32
64	Mutation in the <i>SYNJ1</i> Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism. Human Mutation, 2013, 34, 1208-1215.	2.5	276
65	Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naÃ⁻ve Parkinson's disease. Journal of Neurology, 2013, 260, 1724-1730.	3.6	45
66	Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. Journal of Neurology, 2013, 260, 438-444.	3.6	46
67	Gender differences in non-motor symptoms in early, drug naÃ⁻ve Parkinson's disease. Journal of Neurology, 2013, 260, 2849-2855.	3.6	83
68	Side of onset does not influence cognition in newly diagnosed untreated Parkinson's disease patients. Parkinsonism and Related Disorders, 2013, 19, 256-259.	2.2	28
69	Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. Parkinsonism and Related Disorders, 2013, 19, 1143-1148.	2.2	3
70	Cognitive contributions to gait and falls: Evidence and implications. Movement Disorders, 2013, 28, 1520-1533.	3.9	390
71	The Heterogeneity of Early Parkinson's Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients. PLoS ONE, 2013, 8, e70244.	2.5	150
72	Hearing impairment in Parkinson's disease: Expanding the nonmotor phenotype. Movement Disorders, 2012, 27, 1530-1535.	3.9	93

MARIANNA AMBONI

#	Article	IF	CITATIONS
73	Gait patterns in parkinsonian patients with or without mild cognitive impairment. Movement Disorders, 2012, 27, 1536-1543.	3.9	66
74	Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. Journal of Neurology, 2012, 259, 1808-1813.	3.6	60
75	Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. Neurological Sciences, 2012, 33, 1319-1327.	1.9	25
76	Effect of Global Postural Rehabilitation program on spatiotemporal gait parameters of parkinsonian patients: a three-dimensional motion analysis study. Neurological Sciences, 2012, 33, 1337-1343.	1.9	23
77	Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. Parkinsonism and Related Disorders, 2012, 18, 781-787.	2.2	226
78	Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. Parkinsonism and Related Disorders, 2012, 18, 1034-1038.	2.2	83
79	Future thinking in Parkinson's disease: An executive function?. Neuropsychologia, 2012, 50, 1494-1501.	1.6	108
80	Neuropsychological correlates of theory of mind in patients with early Parkinson's disease. Movement Disorders, 2012, 27, 98-105.	3.9	67
81	Screening LRRK2 gene mutations in patients with Parkinson's disease in Ghana. Journal of Neurology, 2012, 259, 569-570.	3.6	24
82	Parkinson's disease in sub-Saharan Africa: step-by-step into the challenge. Neurodegenerative Disease Management, 2011, 1, 193-202.	2.2	11
83	The "eye of the tiger―sign in pure akinesia with gait freezing. Neurological Sciences, 2011, 32, 703-705.	1.9	4
84	Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion. Movement Disorders, 2011, 26, 1458-1463.	3.9	75
85	Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy. Movement Disorders, 2011, 26, 2578-2580.	3.9	36
86	A twoâ€year followâ€up study of executive dysfunctions in Parkinsonian patients with freezing of gait at onâ€state. Movement Disorders, 2010, 25, 800-802.	3.9	71
87	Multiple system atrophy is associated with changes in peripheral insulinâ€like growth factor system. Movement Disorders, 2010, 25, 2621-2626.	3.9	25
88	Exercise dependence induced by pramipexole in Parkinson's Disease—A Case Report. Movement Disorders, 2010, 25, 2893-2894.	3.9	13
89	Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: An FP-CIT SPECT study. Movement Disorders, 2007, 22, 559-563.	3.9	46
90	A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. Movement Disorders, 2007, 22, 2418-2425.	3.9	84

#	Article	IF	CITATIONS
91	Ropinirole as a Treatment of Restless Legs Syndrome in Patients on Chronic Hemodialysis. Clinical Neuropharmacology, 2004, 27, 178-181.	0.7	84
92	Why do some Friedreich's ataxia patients retain tendon reflexes?. Journal of Neurology, 1999, 246, 353-357.	3.6	36